These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1294 related articles for article (PubMed ID: 17384437)

  • 21. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload.
    Konstam MA; Kiernan M; Chandler A; Dhingra R; Mody FV; Eisen H; Haught WH; Wagoner L; Gupta D; Patten R; Gordon P; Korr K; Fileccia R; Pressler SJ; Gregory D; Wedge P; Dowling D; Romeling M; Konstam JM; Massaro JM; Udelson JE;
    J Am Coll Cardiol; 2017 Mar; 69(11):1409-1419. PubMed ID: 28302292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
    Udelson JE; McGrew FA; Flores E; Ibrahim H; Katz S; Koshkarian G; O'Brien T; Kronenberg MW; Zimmer C; Orlandi C; Konstam MA
    J Am Coll Cardiol; 2007 Jun; 49(22):2151-9. PubMed ID: 17543634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials.
    Xiong B; Huang Y; Tan J; Yao Y; Wang C; Qian J; Rong S; Deng S; Cao Y; Zou Y; Huang J
    Heart Fail Rev; 2015 Nov; 20(6):633-42. PubMed ID: 26334632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
    Matsuzaki M; Hori M; Izumi T; Fukunami M;
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S33-45. PubMed ID: 22120092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure.
    Felker GM; Mentz RJ; Cole RT; Adams KF; Egnaczyk GF; Fiuzat M; Patel CB; Echols M; Khouri MG; Tauras JM; Gupta D; Monds P; Roberts R; O'Connor CM
    J Am Coll Cardiol; 2017 Mar; 69(11):1399-1406. PubMed ID: 27654854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Vaduganathan M; Ambrosy AP; Greene SJ; Mentz RJ; Subacius HP; Maggioni AP; Swedberg K; Nodari S; Zannad F; Konstam MA; Butler J; Gheorghiade M;
    Circ Heart Fail; 2012 Nov; 5(6):750-8. PubMed ID: 23051949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial.
    Gheorghiade M; Pang PS; Ambrosy AP; Lan G; Schmidt P; Filippatos G; Konstam M; Swedberg K; Cook T; Traver B; Maggioni A; Burnett J; Grinfeld L; Udelson J; Zannad F
    Heart Fail Rev; 2012 May; 17(3):485-509. PubMed ID: 21932146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C; Hutchinson DJ
    Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial.
    Mecklai A; Subačius H; Konstam MA; Gheorghiade M; Butler J; Ambrosy AP; Katz SD
    JACC Heart Fail; 2016 Jul; 4(7):580-588. PubMed ID: 27039131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis.
    Wang C; Xiong B; Cai L
    BMC Cardiovasc Disord; 2017 Jun; 17(1):164. PubMed ID: 28633650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure.
    Vaduganathan M; Marti CN; Mentz RJ; Greene SJ; Ambrosy AP; Subacius HP; Fonarow GC; Chioncel O; Bazari H; Maggioni AP; Zannad F; Konstam MA; Sato N; Gheorghiade M; Butler J;
    Am J Cardiol; 2016 Apr; 117(7):1144-50. PubMed ID: 26851146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
    Hauptman PJ; Burnett J; Gheorghiade M; Grinfeld L; Konstam MA; Kostic D; Krasa HB; Maggioni A; Ouyang J; Swedberg K; Zannad F; Zimmer C; Udelson JE;
    J Card Fail; 2013 Jun; 19(6):390-7. PubMed ID: 23743487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
    J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge.
    Matsumoto K; Ehara S; Nakamura Y; Otsuka K; Kawase Y
    Heart Vessels; 2018 Oct; 33(10):1204-1213. PubMed ID: 29687159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial).
    Cook TD; Greene SJ; Kalogeropoulos AP; Fonarow GC; Zea R; Swedberg K; Zannad F; Maggioni AP; Konstam MA; Gheorghiade M; Butler J
    Am J Cardiol; 2016 Feb; 117(4):611-616. PubMed ID: 26742474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasopressin-receptor antagonists in heart failure.
    Schweiger TA; Zdanowicz MM
    Am J Health Syst Pharm; 2008 May; 65(9):807-17. PubMed ID: 18436727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of intravenous OPC-61815 compared with oral tolvaptan in patients with congestive heart failure.
    Sato N; Uno S; Kurita Y; Kim S;
    ESC Heart Fail; 2022 Oct; 9(5):3275-3286. PubMed ID: 35794067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.
    Blair JE; Pang PS; Schrier RW; Metra M; Traver B; Cook T; Campia U; Ambrosy A; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Konstam MA; Gheorghiade M;
    Eur Heart J; 2011 Oct; 32(20):2563-72. PubMed ID: 21785107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolvaptan.
    Plosker GL
    Drugs; 2010 Mar; 70(4):443-54. PubMed ID: 20205486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.